binding was predominantly associated with epithelial tumour cells, the surrounding connective tissue was negative and in several samples high expression of IGF-I -R was found in areas of tumour necrosis. Southern blot analysis of DNAs isolated from 25 ovarian adenocarcinomas revealed no amplification of the IGF-I zyxwvu -R or the EGF-R gene. The HERZ/neu gene was amplified only in 2 out of 3 histologically confirmed endometrioid adenocarcinomas studied but not in 22 other tumours. An amplification of the c-myc gene was observed in 28% (7/25) of the tumours. All c-myc-amplified tumours were PgR-negative. No rearrangement was observed for any of the genes studied. In conclusion, ovarian adenocarcinoma tissues show a decrease in PgR levels and an increased expression of IGF-I -R and EGF-R, in the absence of gene amplification, when compared to benign/ borderline ovarian tumours and normal ovarian tissues. In addition, amplification of the c-myc and HER2/neu genes, without rearrangement of these genes, occurs in a minority of these tumours.
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Ovarian cancer is the leading cause of death from gynaecological cancers. Epidemiological studies show that there are relationships between the incidence of breast, endometrial and ovarian cancer. The vast majority of these female reproductive cancers are of epithelial and not of stromal origin. Steroid hormone receptors are found in the tumour cells of these malignancies (Slamon et al., 1989) . Hormones and growth factors involved in menstrual activity are the likeliest candidates for the aetiology of female reproductive cancers. Analyses have shown that histologic grade, stage of the disease, ploidy and age of the patient appear to influence disease-free survival in ovarian cancer (Rao and Slotman, 1991) . Nevertheless, additional (prognostic) factors in these cancers are needed to define the appropriate treatment for the individual patient. In recent years much attention has been focused on the role of growth factors and the activation of oncogenes in the development of human malignancies. Hormone receptor, growth-factor receptor and oncogene status appeared to be of importance with respect to clinical outcome of breast cancer (Foekens et al., 1991; Klijn et al., 1992; Berns et al., 1992) . For instance, increased expression of epidermal growth factor receptor (EGF-R, c-erbB-1) was associated with poor prognosis in primary breast tumours (Sainsbury etal., 1987) . However, the role of the EGF-R as a prognostic factor in subgroups of breast cancer patients is still under debate (reviewed by Klijn et al., 1992) . The c-erbB-2 gene (HER2 or neu). which shows extensive homology but is distinct from the c-erbB-1 gene, was shown to be amplified or over-expressed in approximately 20% of human mammary tumours (reviewed by: Maguire and Greene, 1989) . It was suggested that amplification of the c-erbB-2 gene was a bad prognostic indicator in node-positive breast-cancer patients (Slamon et al., 1987) , whereas amplification of another oncogene, c-my, may be of prognostic value for patients with node-negative or steroid-receptor-positive breast cancer (Berns et al., 1992) . Data on another membranebound growth-factor receptor, the insulin-like growth factor-1 receptor, are scarce in human primary breast cancer (reviewed by Foekens et ul., 1991) . Studies on prognostic factors in ovarian cancer are limited. Data on EGF-R (c-erbB-1) expression and prognosis in ovarian cancer have been reported (Battaglia et al., 1989; Bauknecht et al., 1990; Berchuck et al., 1991) . Amplification (Slamon et al., 1989) and over-expression (Berchuck et al., 1990) of HER2/neu/c-erbB-2 in primary tumours suggest a worse prognosis for patients with ovarian cancer. The role of c-my amplification and IGF-1-R in ovarian cancer is, as yet, unclear.
The similarities between human breast and ovarian cancer prompted us to study the incidence and role of steroid hormones, growth factors, their receptors and oncogeneamplifications in ovarian carcinogenesis. We have studied the incidence and amount of IGF-1-R, using radioligand binding assays on membrane preparations and/or autoradiography on cryostat sections. The results were compared with those from non-epithelial ovarian tumours, benign and borderline malignancies and normal ovarian tissues. In addition, the incidences of EGF-R, ER and PgR and (onco-)gene amplification were assessed because these factors could be important in tumorigenesis and may eventually assist in a better discrimination between high-and low-risk ovarian cancer patients.
MATERIAL AND METHODS

Patients arid tissues
Tissues of ovarian carcinomas, benign and borderline ovarian tumours and normal ovaries were collected between 1988 and 1989 in our cancer centre. Tissue samples were placed on ice immediately after excision, transported to the laboratory at a temperature below -70°C and stored in liquid nitrogen or at -70°C. The mean age of the patients from whom normal ovarian tissue was obtained was 63 (range: 47-79) and the mean age of the patients with ovarian tumours was 56 (range: 26 to 78). Following the WHO classification (1973) these carcinomas were subtyped into: serous (n = 44), mucinous (14) , endometrioid (8), clear-cell (7), mixed (8) and Rs = 0.89 for PgR. respectively; for both 2p < 0.001, n = 31). The membrane fraction for EGF-R and IGF-1-R dcterminations was obtained in the supernatant fraction after re-homogenization of the 100,000g pellet in 2.5 ml BBB-buffer (20 mM phosphate buffer pH 7.4, containing 0.15 M NaCl and 70 ygiml Bacitracin) on ice with 3 5-sec bursts at 20,000 rpm of an Omni-1000 tissue homogenizer (OMNI, Waterbury, CT). The homogenate was centrifuged for 10 min at 1,00Og, and the supernatant was used as membrane preparation. After an aliquot had been taken for membrane-protein determination, I. 19% (w/v) bovine serum albumin (BSA, purified, Behringwerke, Marburg, Germany) in BBB-buffer was added to a final concentration of 0.1% (w1v) BSA. Aliquots (100 yl) of cell membrane preparations were incubated with 8 concentrations (ranging from 0.15 to 3.5 nM) of 1251-mEGF tracer in a final volunic of 140 yl for 16 hr at 20°C. Non-specific binding was assessed in duplicate using 0.75 nM 1?51-mEGF and a 250-fold excess of non-labelled mEGF. Iodinated mEGF (specific activity 500-600 Ciimmol), prepared by Protag-125 or Enzymobeads as described in detail by Kienhuis zyxwvutsrq et al. (1991) was kindly provided by Dr. Th.J. Benraad (Sint Radboud Hospital, Nijmegen, The Netherlands). Separation of bound and free ligand was performed using hydroxylapatite (HAP) adsorption (Benraad and Foekens. 1990) , with minor modifications. A membrane protein threshold of 0.2 mg/ml was adapted to avoid possible false-negative results. Scatchard analysis of specific 12'I-IGF-1 (S.A. 2000 Ci1mmol: human-Thrs9-analog, Amcrsham, Aylesbury, UK) binding was performed after separation of bound and free ligand by high-speed centrifugation zyxwvutsrqpo as described previously (Foekens et al., 1989) .
Autoradiography
Frozen tissue sections (5 km) originating from 37 human ovarian carcinomas and 9 normal ovaries were stored at -70°C for up to 5 days. Prior to the assay, the slides were brought to room temperature and pre-incubated for 10 min in a PBS solution containing Bacitracin (40 pgiml) and BSA (0.5%); BBB-buffer.
For IGF-1 receptor autoradiography, the cryostat sections were incubated with BBB-buffer containing 100 pM 1'51-IGF-l with or without a 1,000-fold molar excess of unlabeled IGF-I for 2 hr at room temperature. After incubation, the sections were washed 4 times with BBB buffer and subsequently dipped in water and acetone. The sections were air-dried at room temperature and placed against Hyperfilm 3H (Amersham). Slides were exposed for 3 days and the Hyperfilm was processed according to the manufacturer's instructions.
Slides were scored as 1 + (indicating weak specific receptor presence) to 4+ (indicating strong specific receptor presence). Sections of onc of a few breast tumour specimens, which were negative for IGF-1 receptors in Scatchard plot analysis of (MTI) (1). membrane preparations (151214: 7%, Foekens zy ef ul., 1989), were used as a negative control. Human placenta was used as a positive control tissue.
DNA analysis
DNA was isolated from an aliquot of the total tissue homogenate. Southern blotting of EcoR1-digested DNA was performed by standard techniques (Berns et al., 1992) . In brief, digested DNA was size-fractionated on a 0.6% agarose gel and transferred to a nylon membrane (Hybond N Plus, Amersham) and hybridized overnight at 65°C with randomly primed, 32P-dATP-labelled probes (specific activity of 1-2 x 10" cpmikg DNA). EGF-R (EGF receptor probe pHER-A 64-I), HER21 rieu (pHER2-436-1, ATCC 59296); c-myc, an EcoR1-Clal human exon 3-specific c-niyc; and IGF-1-R (pIGF-9-R.8, ATCC 59295) were obtained from ATCC (Rockville, MD). After washing at high stringency (0.3 x SSC), autoradiography with intensifying screens was performed for 1-2 days at -70°C using Kodak XAR-5 films, and autoradiograms were scanned with a Bio-Rad (Richmond, CA) Video densitometer 620. The IGF-1-R probe was used as a control (2 gene copies) for densitometry and for the amount of DNA immobilized on the membrane. In our recent experience (Berns ef al., 1992) concerning measurement of c-niyc and HER21neu amplification in 975 breast tumours, the incidence for c-myc amplification was 17% and that of HER21neu amplification was 19% (these percentages are similar to average percentage values, reported by others).
Statistics
Associations between groups to be compared were assessed by the Spearman rank correlation test. Differences between groups were tested non-parametrically by the Wilcoxon 2-sample test (Mann-Whitney U-test).
RESULTS
IGF-I-R uutoradiography
In all samples, positivity for specific '251-IGF-1 binding was observed by IGF-1-R receptor autoradiography. Tissue sections derived from ovarian adenocarcinomas showed increased density of IGF-1-R (1.5+ to 4+, n = 37) when compared to normal ovarian tissues (1 +, n = 10). In tumours, high density of IGF-1-R was exclusively associated with epithelial tumour cells, while surrounding connective tissue was devoid of specific '251-IGF-I binding. Examples of autoradiograms of 2 tumour tissues with stromal tissue are shown in Figure 1 .
In 71% (517) of the tumours with necrotic areas (7137), high expression of IGF-1-R was observed in these necrotic areas, whereas in 2 tumours necrotic areas were negative for specific '251-IGF-l binding. An example of Iz5I-IGF-l binding in a necrotic area, with histology, is shown in Figure 2 .
EGF-R, IGF-I-R, ER and PgR Scatchard-analysis
The combined EGF-R and IGF-1-R receptor data with respect to median (+ range) and maximum binding capacities and apparent dissociation constants of the various tissue biopsies analyzed are listed in Table I . Fifty-three of the 82 adenocarcinomas studied (65%) were positive for EGF-R by Scatchard analysis, with a median level of 17 fmolimg protein.
The group of adenocarcinomas was composed of 6 subgroups with different histological classifications, and with respect to EGF-R levels, there were no significant differences between these various subgroups (Fig. 3a) . In the combined group of benign tumours (5 cystadenomas, 1 adenofibroma) and borderline malignancies, 57% (8114) and, in the normal ovarian tissues, only 31% (51 16) were positive for EGF-R. There was a near-significant difference (2p = 0.06) between the EGF-R levels in adenocarcinomas and normal ovaries. Epithelial ovarian tumours might be expected to contain a higher EGF-and IGF-1-receptor assays were performed with Scatchard analysis as described in the text. ER and PgR were measured by enzyme immunoassays. Composition of the various groups with respect to different histologically-confirmed subclasses is described in the "Patients" section. +: indicates median content and range, given for receptor-positive tumours only.
percentage of cpithelial cells than normal ovaries. Therefore, it should be realized that the differences in EGF-R levels described may be biased. Four non-epithelial ovarian tumours (2, granulosa-cell turnours, 1 fibrothecoma and 1 MTI) contained high levels of EGF-R, with a median of 58 fmolimg protein.
For IGF-1-R (Table I) , higher levels of IGF-1-R were measured in membrane preparations of adenocarcinomas than in those of the combined group of benign tumours and borderline malignancies or those of normal ovarian tissues. However, in contrast to what was observed for EGF-R, all adenocarcinoma and all combined benigniborderline samples analyzed wcrc positive for IGF-1-R by Scatchard analysis. Nine out of 10 (90%) of the normal ovarian tissucs were positive for IGF-1-R. Four out of 5 non-epithelial ovarian tumours (2 granulosa-cell tumours, zyxwvutsrq 2 fibrothecomas and 1 MTI) containcd very high levels (median 88 fmol/mg protein) of IGF-I-R. In agrcemcnt with the results of autoradiography on frozen scctions, the IGF-1-R levels, measured by Scatchard analysis, were higher in adenocarcinomas than in normal ovarian tissucs (median 64 zyxwvutsr vs. 26 fmol/mg protein). Like the "'I-EGF binding in the various groups, the affinity (K,,) of '2T-IGF-1 lor its receptor in the different tissues analyzed was not different (Table I) .
Cytosolic ER and PgR data are given in Table I . Sixty percent of the adenocarcinoma tissues (55191) were positive for ER ( 2 10 fmol/mg protein), hith a median level of 19 fmolimg protein. In thc combined group of benign/borderlinc tumours 37% and among the normal ovarian tissues 53% were ER-positive. Only 29% of the non-epithelial ovarian tissues (2 out of 7) were ER-positive. The ER levels were not significantly different when adcnocarcinomas were compared with either henign/borderline turnours or normal ovarian tissue. However, ER levels were higher in serous than in mucinous adenocarcinornas (2p = 0.001; Fig. 3b ). When the ER levels of serous or mucinous adenocarcinomas were compared with the combined group of other adenocarcinomas, therc was a near-significant lower or higher level, respectively, in the latter group of tumours (serous vs. others, 2p = 0.06 and mucinous vs. others, 2p = 0.07).
Thirty-eight percent (34/90) of the adenocarcinomas tissues were positive for PgR (2 10 fmolimg protein). Of the benign/ borderline tumours 73% and of the normal tissues 89% were positive. Most pronounced was the observed differencc in the median of thc measured PgR levels, decreasing from 152 fmol mgiprotein in normal tissues, via 33 fmolimg protein in benign/borderline tissues, to 5 frnolimg protein in adenocarcinomas (Table I ). These differences were significant for all groups studied (adenocarcinomas vs. benigniborderline, 2p = 0.0012; adenocarcinomas vs. normal ovaries, 2p < 0.0001 and benigniborderline w. normal ovaries, 2p = 0.018). The levels of PgR in the 6 histologic subgroups of adenocarcinomas did not differ (Fig. 3c) .
In addition, for these adenocarcinoma samples, Spearman regression analysis did not reveal a significant correlation between the levels of EGF-R and ER and of EGF-R and PgR values. whereas there was a weak positive relationship 222 zyxwvutsrqpo BERNS zyxwvutsr ETAL. zyxwvuts (Rs = 0.25, n = 90; 2p < 0.05) between the levels of ER and PgR.
Gene amplification
Twenty-five different DNA samples isolated from adenocarcinorna tissues (14 serous, 4 mucinous, 3 endometrioid, 1 clear-cell, and 3 mixed turnours) were analysed by Southern blotting for amplification or rearrangement of the EGF-R, IGF-I-R, c-myc, and HER2irieii genes. No rearrangement for any of the genes studied in EcoR1-digested DNAs was obscrvcd. No amplification (more than 2 gene copies) of the EGF-R and IGF-R gene was noted (Fig. 4) . Amplification of FIGURE 4-Southern blot of DNA from ovarian adenocarcinoma tissue samples. Total DNA was digested with EcoR1, subjected to electrophoresis, transferred to a nylon membrane and hybridized with c-myc, HER2ineii and IGF-1-R simultaneously. Filters were washed at high stringency and exposed for 2 days, as described in the text. In lanes 22, 23 and 15 amplified oncogenes are shown. the c-niyc gene was found in DNAs from 7 (28%) adenocarcinomas. The tumours which contained an amplified c-tyc gene were all negative for cytosolic PgR, whereas 5 of these turnours were positive for ER. The c-myc amplifications were found in 1 mucinous (10 copies), 1 endometrioid (10 copies), 1 mixed (10 copies), and 4 serous turnours (1 X 10 and 3 x 5 copies). HER2ineu amplifications were only obsqrved in DNA samples isolated from 2 (5 and 10 copies) of the 3 histologically confirmed endometrioid tumours studied. The othcr 22 samples analysed contained diploid amounts of the HER2ineu gene. Figure 4 shows an example of an autoradiogram of EcoRI-digested DNAs probed with a mixture of c-nzyc, HER?/ mi and IGF-I-R probes. One of the 3 mucinous samples analysed showed a co-amplification of the c-myc and HER21 zy neu genes. DISCUSSION We have shown that the levels of EGF-R, IGF-1-R, ER, PgR and gene copy numbers of HER2/rzrri and c-myc vary in ovarian adenocarcinoma, benigniborderline malignancies and normal ovarian tissue.
The median levels of IGF-1-R and ER are approximately twice as high in ovarian adenocarcinoma as in normal ovarian tissue. In contrast, the median level of PgR was about 30 times lower in ovarian adenocarcinoma than in normal ovarian tissue. The frequency of receptor positivity for ER and IGF-I -R was similar in normal, benigniborderline and adenocarcinoma tissues. On the other hand, EGF-R levels were increased (from 31% to 57% to 65%, respectively), and PgR levels were decreased (from 89% to 73% to 38%). respectively). The few cases of non-epithelial tumours studied showed high levels of both EGF-R and IGF-1-R, with low levels of ER and PgR. In breast cancer, higher levels and incidence of IGF-1-R when compared to benign and normal breast tissue have also been reported (Pekonen zyxwv et al., 1988; Peyrat et zyx NI., 1988) . Our autoradiographical analyses revealed that the increased amounts of IGF-1-R are mainly associated with epithelial tumour cells of the ovarian adenocarcinomas, and sometimes with necrosis. The (biological) significance of specific 12sI-IGF-1 binding to these necrotic areas is not clear. It may indicate rapidly growing tumours with insufficient vascularization. In human breast-cancer tissues, specific 12sI-EGF binding has also been observed in necrotic areas by zyxwvutsrq in zyxwvutsr vitro autoradiography (Rcubi and Torhorst, 1988) . This specific binding of growth factors in necrotic tissue indicates the need for histological examination of growth-factor binding and could be useful in predicting a possible heterogeneity of responses of the patient to (future) growth-factor antagonist therapy and/or zyxwvu growth-factor/growth-factor-receptor blocking therapy.
Likc Bauknecht et zyxwvutsrqp a/. Zhangetal. (1989) , we also obscrvcd that the EGF-R gene is not frequently amplified in ovarian tissues. Sincc the IGF-1-R gene is also not amplified, we conclude that amplification of these genes is not involved in ovarian carcinogenesis. However, amplification (20-2696) of the HER2ineu gene (another member of the erbB family) has been reported in ovarian cancer by Zhang zyxwvut et al. (1989) and Slamon et al. (1989) , but we (like Zhou et al., 1988) (1989) did not find any amplification in their study. The c-nzyc amplifications described in our study may be associated with PgR-negativity, since all 7 tumours with an amplified c-nzyc gene werc negative for cytosolic PgR, in spite of ER-positivity in 5 of these 7 cases. Similar results were described for breast canccr, wherc c-nyc amplification was also found to be strongly associatcd with absence of the progesterone receptor (Bernsefal., 1992) . Although there are similarities between breast and ovarian cancer (as described above), the present data show that there are differences as well. In the total group of ovarian adenocarcinomas, we found no negative relationship betwcen EGF-R and ER or PgR (cstahlished by Spearman regression analysis) as observed in breast cancer. This is puzzling, since there is a large body of literature showing a negative relationship between EGF-R and ER or PgR in human breast-tumour biopsies (Klijn et al., 1992) . Also as a prognosticator of survival and response to endocrine therapy, there is a disparity regarding the presence of prognostic significance of ER in breast cancer, and the absence of prognostic value of ER in ovarian cancer (Rao and Slotman, 1991) . On the other hand, the levcls of the oestrogen-regulated PgR appear to be of prognostic value in both ovarian carcinoma (Rao and Slotman, 1991) and breast cancer (Foekens et zyxw d., zyx   101 ). From these data we suggest that the role of the oestrogcn receptor may be different in ovarian and in breast cancer. In ovarian cancer chromosome 6q, the locus of the ER is often affected (Zhcng et al., 1991) . Furthermore, the expression of pS2, an oestrogen-regulated protein in breast cancer, is negative or low in ovarian cancers as measured by immuno-radiometric assays for pS2 (Foekens ef al., 1990) . Moreover, mRNA expression of pS2 appeared to be poorly correlated with ER in ovarian carcinomas (Wysocki et al., 1990) . It would therefore be of intcrest to study the expression of other ER-regulated genes, like cathepsin D, in ovarian cancer, to obtain more insight into ovarian carcinogenesis and biology. Indeed, in a recent report (Scambia et al., 1991) it was suggested that cathcpsin D was not correlated with ER expression.
The determination of possible prognostic or therapeutic significance of gene amplification or over-expression and growth-factor receptors (EGF-R) in ovarian cancer, as described by Bauknecht et al. (1990) . is currcntly under investigation.
